Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | PRKCA | P17252 | 9/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828718 | 1.00 | MAPT (0.47) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL11568385 | 0.93 | PRKCA (0.48) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| Oxirane SCHEMBL7557475 | 0.83 | MAPT (0.53) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013128 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013189 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013205 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Propylene Oxide SCHEMBL6941925 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013104 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013087 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL15013199 | 0.82 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078058-B1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | EVONIK DEGUSSA GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20100092411-A1 | HYDROPHOBIC ZINC OXIDE POWDER | EVONIK DEGUSSA GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100040567-A1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | EVONIK DEGUSSA GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100008872-A1 | SILICA COATED ZINC OXIDE PARTICLES OBTAINABLE BY A FLAME PYROLYSIS PROCESS | EVONIK DEGUSSA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2061723-B1 | OXIDE PARTICLES COMPRISING ZINC AND MANGANESE | EVONIK DEGUSSA GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040567-A1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | ZKSCAN2, BET1, ZRANB2 | MAPT 678/4885MAPK1 4083/4885LMNA 3219/4885 |
| US-20100092411-A1 | HYDROPHOBIC ZINC OXIDE POWDER | SLC30A7, SLC39A3, SOD1 | MAPT 814/4885MAPK1 4544/4885LMNA 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.